BioSpace News Archive

Business

ADC Therapeutics to Appoint Peter Hug, Ph.D., to Board of Directors

ADC Therapeutics today announced that Peter Hug, Ph.D., will be appointed to its board of directors. Dr. Hug is a 35-year veteran of Roche.

January 7, 2019
·
2 min read
Microbix Enhances Quality Management System

ISO 13485:2016 Medical Devices Certification Attained

January 7, 2019
·
5 min read
Eisai’s Etak Antimicrobial Spray Alpha Wins Nikkei Business Daily Awards for Superiority at the 2018 Nikkei Superior Products and Services Awards

For Dealing with Viruses and Bacteria! Antimicrobial Barrier that Lasts for 1 Week

January 7, 2019
·
3 min read
Drug Development

A New Day, a New Vant. Roivant Launches Alyvant Ahead of J.P. Morgan 2019

Biotech entrepreneur Vivek Ramaswamy has launched another subsidiary for Roivant Sciences. Ramaswamy will provide an update on the new company, as well as other members of the Roivant family during a Monday presentation at JPM19.

January 7, 2019
·
3 min read
·
Alex Keown
Job Trends

Allergan Establishes R&D Center in Kendall Square to Open in Q1 2019

The white-hot biotech hub of Kendall Square just got a little bit more crowded. Ireland-based Allergan plc announced this morning that the company will establish an R&D facility in the Cambridge, Mass. neighborhood.

January 7, 2019
·
2 min read
·
Alex Keown
Business

Sanofi and Regeneron Restructure Immuno-Oncology Collaboration to Add Two New Products

Tarrytown, NY-based Regeneron Pharmaceuticals and Paris-based Sanofi restructured a 2015 agreement to develop immuno-oncology (I/O) treatments. That deal was scheduled to wrap in 2020, but the revision adds two clinical-stage bispecific antibodies to the collaboration.

January 7, 2019
·
2 min read
·
Mark Terry
Business

AstraZeneca Taps Controversial Former MSK CMO Jose Baselga to Head Oncology R&D

Baselga resigned from Memorial Sloan Kettering following reports he failed to disclose his financial ties to various pharma companies in articles he published.

January 7, 2019
·
3 min read
·
Alex Keown
Drug Development

Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis

Galapagos NV expands its clinical study program with GLPG1690 in systemic sclerosis, following the recent start of the ISABELA Phase 3 program with ‘1690 in IPF.

January 7, 2019
·
5 min read
Epigenomics AG Announces Positive Results from Microsimulation Model

January 7, 2019
·
2 min read
Policy

Achievement of two major development milestones

IDE application submitted to the FDA for HEMOSNOWTM

January 7, 2019
·
4 min read